Name Address/P.O. Box Postal Code/City Country Contact Person Telephone Fax Email Website Social Media Number of Employees Founded (year) Type of Laboratory
›
›
Herbert-Bayer-Str. 8 13086 Berlin Germany Dr Lutz Hilbrich (CEO) +49-30-322-935-100 +49-30-322-935-400 info@probiogen.de cmo@probiogen.de www.probiogen.de
›
IQ
› › › › › › ›
› › ›
Areas of Activity
›
Biological Patents
›
External Collaborations
Request for Further Collaborations
ProBioGen AG
›
›
240 1994 S1, S2 l Biopharmaceutical development and GMP production facility l Biopharmaceutical contract development and manufacturing l Proprietary technologies for improving product characteristics and process efficiency ProBioGen holds numerous international patents on technologies to improve product quality/potency and enhance cellular productivity. With many international companies and research organisations, e.g. Boehringer Ingelheim, Bayer, CRISPR, Novartis, etc. ProBioGen works with biotech and pharma companies that develop complex therapeutic glycoproteins or viral vaccines. Services include cell line and process development up to GMP manufacturing, using animal and human cell lines. In addition, proprietary product/process-improving technologies are out-licensed.
Intelligent biopharmaceutical solutions Internationally renowned specialist for developing and manufacturing complex biopharmaceutical active ingredients with the aid of state-of-the-art services and innovative technologies, with manufacturing authorisation for human biopharmaceuticals according to FDA/EMA standards.
Experience & client feedback For over 27 years we have been a successful development and manufacturing partner for leading biotechs and pharmas on novel products, biosimilars, e.g. mAbs, Fc-fusion proteins, clotting factors, and enzymes. Clients value our scientific expertise, excellent working relationships, and outstanding flexibility.
Unique services Quality development services We offer true “one-stop-shop” complete service packages from early lead optimization, rapid and integrated development of high-producer cell lines, processes, and analytical methods, up to full GMP manufacturing programmes. Our comprehensive analytics portfolio includes IPCs, release tests, and in vitro bioactivity assays. Innovative technology platforms to optimise yields, boost product potency, increase development speed, and cut manufacturing costs; all independently available for licensing. Integrated cell line and process development Our pharmaceutical cell line development with CHO.RiGHT® platform includes proprietary, royalty- and license-free expression vector technology, DirectedLuck™ transposase, CHO host cells, and our own chemically defined media platform. The excellent reputation of our cell line development skills is based on fine-tuned, individually tailored clone selection procedures and early integration of upstream and downstream selection parameters. This allows the selection of the optimal expression strategy for each protein and enables rapid and economic upstream process development. Reliable and flexible contract manufacturing We offer GMP production in fully state-of-the art disposable systems in fed-batch and continuous processes in up to 1000L bioreactors, including:
